Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TD-9855 Group 1 · 1 trial · 1 indication
Pain NRS score is based on an 11-point scale where 0 represents no pain and 10 represents the worst possible pain.
| Arm | Type | Description |
|---|---|---|
| TD-9855 Group 1 | EXPERIMENTAL | Group 1 to be dosed with TD-9855 |
| TD-9855 Group 2 | EXPERIMENTAL | Group 2 to be dosed with TD-9855 |
| Placebo | PLACEBO_COMPARATOR | Group to be dosed with Placebo |
| Name | Type | Description |
|---|---|---|
| TD-9855 Group 1 | DRUG | - |
| TD-9855 Group 2 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * • American College of Rheumatology (ACR) Diagnostic Criteria for Fibromyalgia (FM) * Informed consent * 18 to 65 years of age * Discontinue therapy with adrenergic-acting drugs, and certain other medications * Only acetaminophen or NSAID as rescue pain medication ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Axsome Therapeutics, Inc. | AXSM | 1 | PHASE3 | AXS-14 |
| Grace Therapeutics, Inc. | GRCE | 1 | - | Undisclosed |
TD-9855 is an investigational small molecule being studied for the treatment of fibromyalgia, a chronic condition characterized by widespread musculoskeletal pain. It is being developed by Theravance Biopharma, Inc. and is currently in clinical development, though it is not approved for any use.
The specific molecular target of TD-9855 has not been disclosed in available information. It is a small molecule being evaluated for its potential to treat fibromyalgia, but its mechanism of action is not publicly detailed.
TD-9855 is being developed by Theravance Biopharma, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol TBPH. The company is conducting clinical trials to evaluate the drug's safety and efficacy for fibromyalgia.
TD-9855 is in Phase 2 clinical development. A Phase 2 study has been completed, and the drug remains investigational. It has not been approved by regulatory authorities, and its development status is subject to ongoing clinical evaluation.
TD-9855 has been studied in a completed Phase 2 clinical trial registered as NCT01693692, titled 'Phase 2 Study of TD-9855 to Treat Fibromyalgia.' The trial enrolled 392 participants in the United States and was randomized, double-blind, and placebo-controlled.
No alternative names for TD-9855 have been identified in available information. It is referred to solely as TD-9855 in clinical trial records and by its developer, Theravance Biopharma, Inc.